ArticleAdvances in experimental medicine and biology2021
Synopsis of Clinical Acute Respiratory Distress Syndrome (ARDS).
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Beyond immunomodulation: mechanisms and synergistic strategies of mesenchymal stem cells in promoting alveolar epithelial and endothelial repair in ARDS.Frontiers in immunology · 2026Review
- Association of ratios of visceral fat area/subcutaneous fat area and muscle area/standard body weight at T12 CT level with the prognosis of acute respiratory distress syndrome.Chinese medical journal pulmonary and critical care medicine · 2024Article
- Article
- Network analysis-based strategy to investigate the protective effect of cepharanthine on rat acute respiratory distress syndrome.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The entity of acute respiratory distress syndrome (ARDS) is an acute inflammatory lung condition associated with lung damage and increased vascular permeability. In the ICU, ARDS was reported to be the cause of 10.4% of admissions. The syndrome is associated with conditions such as sepsis, burns, trauma, and many others. The Berlin Definition which is the most up-to-date definition defines ARDS as an early onset of severe and refractory hypoxemia, PaO2/FiO2 ratio less than 300 mmHg, bilateral infiltrates on chest x-ray, and alveolar edema not explained by a cardiogenic cause or fluid overload.The entity of ARDS and its treatment have been studied for many years to better understand it and help find therapies. However, the mainstay of medical management is supportive with specific strategies for mechanical ventilation. No specific drug therapy is available at present.In this chapter, the history, clinical picture, and therapeutic approaches to ARDS will be discussed. We include lung-protective ventilation, prone positioning, use of neuromuscular blockade, corticosteroids, as well as discussion of studies done on this important clinical and morbid condition. We emphasize that there are ongoing trials and research being done to better identify patients earlier in their clinical course so that supportive care with lung-protective ventilation and a conservative fluid approach can be implemented. We also mention promising therapies such as cell-based therapies which would help in decreasing lung inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.